Bio-Rad Launches qUAntify Advance Control for Urinalysis Testing

Date: 
2019-01-22

Press Release

Bio-Rad Launches qUAntify Advance Control for Urinalysis Testing

HERCULES, Calif.–January 22, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostics products, today announced the launch of qUAntify Advance Control for use in clinical labs performing urinalysis testing.  

The qUAntify Advance Control is an independent quality control used to monitor the precision of laboratory urinalysis test procedures. The control contains human urine solution and offers 31 days of open vial stability for all analytes, including ketones, at room temperature. This provides clinicians and lab professionals added convenience with storing the product after opening.

The Unity Interlaboratory Program and Unity QC Data Management Solutions, designed to improve the effectiveness of the laboratory’s statistical process control, are available for use with qUAntify Advance.

For more information about Bio-Rad’s qUAntify Advance, please visit: http://www.qcnet.com/urinalysis.


About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Radnobr> had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio rad.com.


This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com